Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 12/20 | 0.78 |
| ▸ | CHUK | O15111 | 10/20 | 0.78 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4689422 | 0.90 | IKBKB (0.97) | IKBKBCHUKPDPK1 | |
| SCHEMBL3802579 | 0.88 | IKBKB (1.00) | IKBKBCHUKPDPK1 | |
| SCHEMBL4689165 | 0.87 | IKBKB (0.91) | IKBKBCHUKPDPK1KEAP1 | |
| SCHEMBL4686157 | 0.84 | IKBKB (0.76) | IKBKBCHUKPDPK1KEAP1CHEK2 | |
| SCHEMBL4685550 | 0.83 | IKBKB (0.74) | IKBKBCHUKPDPK1KEAP1ESR1 | |
| SCHEMBL27658383 | 0.82 | IKBKB (0.78) | IKBKBCHUKPDPK1ADRB1 | |
| SCHEMBL4685346 | 0.82 | IKBKB (1.00) | IKBKBCHUKPDPK1 | |
| SCHEMBL4685618 | 0.82 | IKBKB (0.74) | IKBKBCHUKPDPK1CDC7 | |
| SCHEMBL4685171 | 0.82 | IKBKB (0.72) | IKBKBCHUKPDPK1CDC7KEAP1 | |
| SCHEMBL4687034 | 0.82 | IKBKB (1.00) | IKBKBCHUKPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | claimed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | claimed |
| CN-1933830-A | Indole derivatives and their use as kinase inhibitors, in particular IKK2 inhibitors | SMITHKLINE BEECHAM CORP (US) | 2007-03-21 | — | — | CN | claimed |
| EP-1703905-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-27 | — | — | EP | claimed |
| WO-2005067923-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-28 | — | — | WO | claimed |
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| CN-1933830-A | Indole derivatives and their use as kinase inhibitors, in particular IKK2 inhibitors | SMITHKLINE BEECHAM CORP (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1703905-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005067923-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | NFKBIA, IKBKB, IDO2 | IKBKB 2/4885CHUK 6/4885PDPK1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.